Developed by Co-Founder Professor Rajneesh Verma, the Legacinetics approach builds on decades of experience and collaboration with Nobel Laureate Professor Shinya Yamanaka.
By optimising iPSC-to-iMSC technology and focusing on exosome therapies, Legacinetics offers a scalable, safe platform for regenerative medicine, disease modelling, and drug discovery, addressing key challenges in clinical translation.
MSC and IMSC therapies face challenges such as pulmonary risks and regulatory limits, but MSC exosomes offer a safer, scalable alternative.
These small vesicles carry powerful therapeutic molecules, driving advances in regenerative medicine, immunology, neurology, oncology, and drug delivery as a next-generation treatment platform.
Legacinetics is pioneering IMSC-Exosome technology through the development of a global haplobank, enabling the creation of cost-effective, IP-protected cell lines for highly targeted allogenic therapies.
By combining advanced AI, machine learning, and world-leading scientific expertise, we are delivering next-generation treatments with exceptional safety profiles and proven clinical efficacy.
With shared global experience across major markets including Australia, China, India, Thailand, New Zealand, Japan, UAE & Africa, the Legacinetics story is one of a shared vision of accelerated human wellness, scientific advances and global academic influence and leadership.
Legacinetics was founded by Professor Rajneesh Verma PhD, and James Scuderi, who together lead a team of highly experienced scientists, technicians and regenerative health practitioners from across the world.
Whether you're interested in our services, seeking partnerships, or simply want to learn more about what we do, our team is here to assist! Contact us to discuss how you can benefit from partnering with Legacinetics.
